SCHEMBL3352524

SCHEMBL3352524

Cc1nc2ccc(C(F)(F)F)cn2c1-c1csc(C2(c3ccc(C(=O)NO)cc3)CCCC2)n1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.38
AKT2 P31751 2/20 0.38
GABRD O14764 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRA4 P48169 1/20 0.36
HDAC1 Q13547 3/20 0.36
HDAC6 Q9UBN7 3/20 0.36
HDAC3 O15379 1/20 0.36
HDAC2 Q92769 1/20 0.36
MCHR1 Q99705 4/20 0.35
PDE2A O00408 2/20 0.35
HDAC4 P56524 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC9 Q9UKV0 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34
CTSL P07711 1/20 0.32
CTSB P07858 1/20 0.32
CTSS P25774 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3350978 0.97 GABRD (0.37) AKT1AKT2GABRDGABRB1GABRA4
SCHEMBL199623 0.93 KCNH2 (0.37) AKT1AKT2GABRDGABRB1GABRA4
SCHEMBL3351453 0.89 HDAC1 (0.40) AKT1AKT2GABRDGABRB1GABRA4
SCHEMBL3355103 0.88 AKT1 (0.36) AKT1AKT2HDAC1HDAC6HDAC3
SCHEMBL3350568 0.88 ALDH1A1 (0.39) AKT1AKT2GABRDGABRB1GABRA4
SCHEMBL3355420 0.88 HDAC1 (0.45) GABRDGABRB1GABRA4HDAC1HDAC3
SCHEMBL3353149 0.86 HDAC1 (0.38) AKT1AKT2HDAC1HDAC6HDAC3
SCHEMBL3352449 0.85 HDAC1 (0.41) AKT1AKT2GABRDGABRB1GABRA4
SCHEMBL3354088 0.85 HDAC6 (0.36) AKT1AKT2HDAC1HDAC6HDAC3
SCHEMBL3348622 0.84 HDAC1 (0.46) GABRDGABRB1GABRA4HDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198299-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-06-12 US claimed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 AKT1 1338/4885AKT2 981/4885GABRD 3316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.